MA44862A - Formulations de fulvestrant et méthodes d'utilisation de celles-ci - Google Patents
Formulations de fulvestrant et méthodes d'utilisation de celles-ciInfo
- Publication number
- MA44862A MA44862A MA044862A MA44862A MA44862A MA 44862 A MA44862 A MA 44862A MA 044862 A MA044862 A MA 044862A MA 44862 A MA44862 A MA 44862A MA 44862 A MA44862 A MA 44862A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- fulvestrant formulations
- fulvestrant
- formulations
- Prior art date
Links
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title 1
- 229960002258 fulvestrant Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332842P | 2016-05-06 | 2016-05-06 | |
| US201662420555P | 2016-11-10 | 2016-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44862A true MA44862A (fr) | 2019-03-13 |
Family
ID=58709642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044862A MA44862A (fr) | 2016-05-06 | 2017-05-05 | Formulations de fulvestrant et méthodes d'utilisation de celles-ci |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190134059A1 (https=) |
| EP (1) | EP3452011A1 (https=) |
| JP (3) | JP2019516789A (https=) |
| KR (1) | KR102438425B1 (https=) |
| CN (1) | CN109310621A (https=) |
| AU (2) | AU2017261321B2 (https=) |
| CA (1) | CA3022834A1 (https=) |
| CO (1) | CO2018013257A2 (https=) |
| IL (2) | IL285928B2 (https=) |
| MA (1) | MA44862A (https=) |
| MX (2) | MX2018013414A (https=) |
| MY (1) | MY205661A (https=) |
| UA (1) | UA125514C2 (https=) |
| WO (1) | WO2017193048A1 (https=) |
| ZA (1) | ZA201807031B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11590077B2 (en) | 2016-05-06 | 2023-02-28 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| EP3706719A1 (en) | 2017-11-08 | 2020-09-16 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations and methods of their use |
| EP4074304A4 (en) * | 2019-12-11 | 2024-01-10 | Shanghai Bocimed Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION OF FULVESTRANT, PREPARATION METHOD AND APPLICATION THEREOF |
| CN113694017B (zh) * | 2020-05-11 | 2024-04-02 | 鲁南制药集团股份有限公司 | 一种氟维司群注射制剂及其制备方法 |
| CN114504551B (zh) * | 2020-11-16 | 2024-01-02 | 北京厚燊维康科技有限责任公司 | 可用于光动力治疗或诊断的制剂 |
| CN120284882A (zh) * | 2020-12-10 | 2025-07-11 | 上海云晟研新生物科技有限公司 | 氟维司群药物组合物、其制备方法及应用 |
| JP2024545690A (ja) * | 2021-12-20 | 2024-12-10 | サムヤン、ホールディングス、コーポレーション | 溶解度が改善されたフルベストラントの医薬組成物及びその製造方法 |
| KR20240105964A (ko) * | 2022-12-29 | 2024-07-08 | 주식회사 삼양홀딩스 | 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
| US6495534B2 (en) * | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
| WO2001087262A2 (en) | 2000-05-15 | 2001-11-22 | Pharmacia Italia S.P.A. | Stabilized steroidal suspension |
| PL367624A1 (en) * | 2001-07-07 | 2005-03-07 | Astrazeneca Ab | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| GB0116619D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| JP2003298516A (ja) | 2002-03-29 | 2003-10-17 | Fujitsu Ltd | 波長分散補償装置 |
| CA2575906C (en) * | 2004-08-04 | 2014-04-15 | Camurus Ab | Compositions forming non-lamellar dispersions |
| KR101429774B1 (ko) | 2005-05-09 | 2014-10-02 | 바이오스피어 메디칼 에스.에이. | 마이크로스피어 및 비이온성 조영제를 사용하는 조성물 및방법 |
| WO2007069272A2 (en) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CN101108168B (zh) * | 2007-08-03 | 2010-12-08 | 西安力邦医药科技有限责任公司 | 一种氟维司群缓释微球的制备方法 |
| SI2200588T1 (sl) | 2007-09-25 | 2019-08-30 | Solubest Ltd. | Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo |
| JP2011514349A (ja) | 2008-03-07 | 2011-05-06 | サイドース・エルエルシー | フルベストラント配合物 |
| TW201016220A (en) * | 2008-10-31 | 2010-05-01 | Scinopharm Taiwan Ltd | Micronization form of 7α-[9-(4,4,5,5,5-pentafluoropentylsufinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol and process for the preparation thereof |
| MX2011013797A (es) | 2009-06-18 | 2012-01-30 | Abbott Lab | Suspension de farmaco estable de nanoparticula. |
| WO2011022861A1 (zh) * | 2009-08-31 | 2011-03-03 | 西安力邦医药科技有限责任公司 | 氟维司群纳米球/微球及其制备方法和用途 |
| WO2011011978A1 (zh) * | 2009-07-31 | 2011-02-03 | 西安力邦医药科技有限责任公司 | 微球药物载体、其制备方法、组合物及应用 |
| WO2012021791A2 (en) | 2010-08-13 | 2012-02-16 | Scidose Llc | Aqueous formulation with improved stability |
| CN103221052A (zh) | 2010-09-16 | 2013-07-24 | 施摩达生物技术有限公司 | 氟维司群组合物及使用方法 |
| EP2468258A1 (en) | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
| EP2661281B1 (en) | 2011-01-09 | 2021-03-10 | ANP Technologies, Inc. | Hydrophobic molecule-induced branched polymer aggregates and their use |
| EP2711010B1 (en) * | 2011-05-20 | 2018-10-31 | Capital, Business Y Gestión De Finanzas, S.L | Pharmaceutical composition |
| CN102915088A (zh) | 2011-08-03 | 2013-02-06 | 鸿富锦精密工业（深圳）有限公司 | 资料存储器固定装置 |
| US11179468B2 (en) * | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
| CA2869377C (en) | 2012-04-09 | 2022-11-08 | Scidose, Llc | Fulvestrant formulations |
| WO2013182668A1 (en) * | 2012-06-08 | 2013-12-12 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| CN104337761B (zh) * | 2013-08-07 | 2019-03-26 | 江苏豪森药业集团有限公司 | 氟维司群药物组合物 |
| WO2015033302A2 (en) * | 2013-09-06 | 2015-03-12 | Salah Uddin Ahmed | Fulvestrant compositions |
| JP2016536282A (ja) * | 2013-10-03 | 2016-11-24 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ＰＩ３Ｋα阻害剤を使用する強化された治療レジメン |
| HUP1300646A2 (en) | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| PT107433B (pt) | 2014-01-28 | 2018-12-04 | Hovione Farm S A | Processo de redução e controlo do tamanho de partícula |
| US9271990B2 (en) | 2014-02-14 | 2016-03-01 | Fresenius Kabi Usa, Llc | Fulvestrant formulations |
| JP6235755B2 (ja) | 2014-07-02 | 2017-11-22 | ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク | 高いカーゴ対サーファクタント比を有するサーファクタント除去ミセル組成物 |
| CN104434808A (zh) | 2014-07-03 | 2015-03-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种治疗性纳米粒子及其制备方法 |
-
2017
- 2017-05-04 IL IL285928A patent/IL285928B2/en unknown
- 2017-05-05 US US16/099,265 patent/US20190134059A1/en not_active Abandoned
- 2017-05-05 KR KR1020187034942A patent/KR102438425B1/ko active Active
- 2017-05-05 MX MX2018013414A patent/MX2018013414A/es unknown
- 2017-05-05 CA CA3022834A patent/CA3022834A1/en active Pending
- 2017-05-05 JP JP2019510578A patent/JP2019516789A/ja active Pending
- 2017-05-05 WO PCT/US2017/031376 patent/WO2017193048A1/en not_active Ceased
- 2017-05-05 EP EP17723902.7A patent/EP3452011A1/en active Pending
- 2017-05-05 AU AU2017261321A patent/AU2017261321B2/en active Active
- 2017-05-05 MY MYPI2018703903A patent/MY205661A/en unknown
- 2017-05-05 CN CN201780027809.5A patent/CN109310621A/zh active Pending
- 2017-05-05 MA MA044862A patent/MA44862A/fr unknown
- 2017-05-05 UA UAA201812019A patent/UA125514C2/uk unknown
-
2018
- 2018-10-18 IL IL262465A patent/IL262465A/en unknown
- 2018-10-22 ZA ZA2018/07031A patent/ZA201807031B/en unknown
- 2018-11-01 MX MX2022013199A patent/MX2022013199A/es unknown
- 2018-12-06 CO CONC2018/0013257A patent/CO2018013257A2/es unknown
-
2021
- 2021-07-19 US US17/379,534 patent/US12370199B2/en active Active
- 2021-07-19 JP JP2021118471A patent/JP7312523B2/ja active Active
-
2023
- 2023-05-26 JP JP2023086732A patent/JP2023109959A/ja active Pending
- 2023-05-31 AU AU2023203392A patent/AU2023203392A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MY205661A (en) | 2024-11-04 |
| BR112018072768A2 (pt) | 2019-02-19 |
| UA125514C2 (uk) | 2022-04-13 |
| IL262465A (en) | 2018-12-31 |
| MX2018013414A (es) | 2019-06-06 |
| CA3022834A1 (en) | 2017-11-09 |
| JP2019516789A (ja) | 2019-06-20 |
| EP3452011A1 (en) | 2019-03-13 |
| AU2017261321B2 (en) | 2023-03-09 |
| JP2021169510A (ja) | 2021-10-28 |
| CO2018013257A2 (es) | 2018-12-28 |
| WO2017193048A1 (en) | 2017-11-09 |
| US20190134059A1 (en) | 2019-05-09 |
| MX2022013199A (es) | 2022-12-13 |
| US12370199B2 (en) | 2025-07-29 |
| AU2017261321A1 (en) | 2018-11-15 |
| AU2023203392A1 (en) | 2023-06-29 |
| JP2023109959A (ja) | 2023-08-08 |
| CN109310621A (zh) | 2019-02-05 |
| KR20190005183A (ko) | 2019-01-15 |
| RU2018142068A3 (https=) | 2020-09-17 |
| KR102438425B1 (ko) | 2022-09-01 |
| IL285928A (en) | 2021-10-31 |
| ZA201807031B (en) | 2023-10-25 |
| IL285928B1 (en) | 2025-02-01 |
| JP7312523B2 (ja) | 2023-07-21 |
| US20210346396A1 (en) | 2021-11-11 |
| RU2018142068A (ru) | 2020-06-08 |
| IL285928B2 (en) | 2025-06-01 |
| NZ747911A (en) | 2025-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3337517A4 (en) | ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE | |
| EP3402549A4 (en) | MICRONADELE COMPOSITIONS AND METHOD FOR USE THEREOF | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| EP3429591A4 (en) | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE | |
| EP3694529A4 (en) | TRISPECIFIC PROTEINS AND METHOD OF USE | |
| MA49403A (fr) | Compositions de pde5 et méthodes d'immunothérapie | |
| MA48579A (fr) | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci | |
| EP3383431A4 (en) | ANTI-GITR ANTIBODIES AND METHOD OF USE THEREOF | |
| MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
| MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
| EP3383430A4 (en) | ANTIBODIES AND METHOD FOR USE THEREOF | |
| EP3355954A4 (en) | RELEASE PROCEDURE AND COMPOSITIONS | |
| EP3373969A4 (en) | GLYCANINTERAGING COMPOUNDS AND METHOD OF USE | |
| EP3328363A4 (en) | COMPOSITIONS AND METHOD FOR IMMUNOMODULATION | |
| EP3551209A4 (en) | INSULIN FC FUSIONS AND METHOD FOR USE | |
| MA44862A (fr) | Formulations de fulvestrant et méthodes d'utilisation de celles-ci | |
| EP3319611A4 (en) | OXYSTEROLS AND METHOD OF USE THEREOF | |
| EP3474857A4 (en) | COMPOSITIONS AND METHOD FOR DELIVERING THERAPY AGENTS | |
| EP3525583A4 (en) | ANTI-CS1 ANTIBODIES AND METHOD FOR USE THEREOF | |
| EP3383917A4 (en) | Novel anti-claudin antibodies and methods of use | |
| MA44526A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| EP3684819A4 (en) | Anti-ykl40 antibodies and methods of use | |
| EP3728323A4 (en) | ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE | |
| MA43282A (fr) | Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées | |
| MA46422A (fr) | Oligonucléotides modifiés et méthodes d'utilisation |